• Login
Forest Laboratories
Divisions and Subsidiaries
  • Forest Pharmaceuticals
  • Forest Laboratories Europe
  • Cerexa, Inc.
  • Forest Laboratories Canada Inc.
  • About Forest
        • Overview
          • Forest identifies, develops, and delivers therapies that make a meaningful difference in people's lives
        • Products
        • Research
        • News
  • Investor Center
        • Overview
          • Forest is building on a strong track record of commercial achievement to deliver important new medicines and strengthen our therapeutic franchises
        • Annual Reports
        • Stock Information
        • Webcasts &
          Presentations
  • Partnerships
        • Overview
          • Forest partners with biotech and pharmaceutical companies to develop and bring promising new medicines to market
        • Capabilities
  • Careers
        • Overview
          • Joining Forest is an opportunity to become part of a forward-thinking community dedicated to helping improve patients' lives through medicine
        • Job Search
  • About Forest
  • Products
  • Research
  • News
    • Media Resources
    • Press Release Archive
    • All Press Releases
    • Business Development News
    • Corporate News
    • Financial News
    • Product News
    • R&D News

All Press Releases

  • 06.24.2004
    Forest Announces Results of Recently Completed Lexapro(R) Pediatric Depression Clinical Trial
  • 06.24.2004
    Forest Discusses Disclosure of Citalopram Clinical Trial Data in Children and Adolescents
  • 05.06.2004
    Depressed Patients Showed Improvement with Lexapro(TM) After Failure with Initial SSRI Treatment
  • 05.06.2004
    Namenda(TM) (memantine HCl) Provides Functional and Behavioral Benefits in Patients with Moderate to Severe Alzheimer's Disease
  • 04.28.2004
    New Data Highlight Positive Effect of Namenda(TM) on Brain Activity in Patients With Mild to Moderate Alzheimer's Disease
  • 04.20.2004
    Forest Laboratories Reports Earnings Per Share of $0.38 for Fiscal Fourth Quarter
  • 04.16.2004
    Forest Laboratories Receives Notification of ANDA Filing For a Generic Equivalent of Lexapro(R)
  • 04.14.2004
    Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2004 Fourth Quarter and Full Year Earnings
  • 03.15.2004
    Lexapro(R) as Effective as Paxil(R) and Well Tolerated in the Treatment of Generalized Anxiety Disorder
  • 03.15.2004
    ChemoCentryx and Forest Laboratories to Collaborate on Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics
  • « first
  • ‹ previous
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • next ›
  • last »

ABOUT FOREST

With a unique partnership-focused business model and a strong track record of commercial achievement, Forest has built a pharmaceutical business for today's environment. The Company is fulfilling its objective of making a meaningful difference in patients' lives through an expanded and diversified product portfolio and the most robust pipeline in our history.

CAREERS AT FOREST

Forest employees are driven by a shared passion to help improve patients' lives through medicine. Forest offers a variety of opportunities for experienced professionals, sales professionals, graduate students, and others to build their careers in a collaborative environment. Learn more about joining our team.

 

  • Legal Statement
  • Privacy Policy
  • Contact Us
  • Site Map
© Forest Laboratories, Inc.    085-13000018 6/13